ORIGINAL ARTICLE Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes M.N. Kosiborod and Others Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations, and body weight than placebo at 1 year. Read the article. |
No comments:
Post a Comment